A Boston-based venture firm specializes in early stage opportunities in med-tech, diagnostics, and instruments. Currently, the firm has a total AUM of $125 million. Typically, the firm initially invests in a start-up at the early stage, but reserves capital for participation later on. The firm typically makes a first investment in the range of $1-3 million, but is open to making larger or smaller allocations as opportunities arise. The firm expects to invest a total in the range of $7-12 million in a given portfolio company as it makes progress toward a successful exit. The firm prefers to act as a lead investor for early stage deals.

The firm is most interested in companies developing Medical devices, Diagnostics tools and Instrumentation. The firm is looking for companies targeting global unmet clinical needs in areas such as oncology, cardiovascular disease, obesity, and women’s health. The firm is willing to invest in companies that are pre-prototype as well as those that have a working prototype of their product.

The firm looks to act as a long term strategic partner with its portfolio companies. The firm looks for experienced management teams and generally looks to take a board seat into companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A non-profit foundation is dedicated to accelerating the adoption of focused ultrasound to be used with therapeutic treatments. The foundation provides funding in the form of non-dilutive research grants as well as equity investments within early stage technologies that utilize focused ultrasound within their therapies. Examples include the use of focused ultrasound as a drug delivery mechanism. The foundation invests globally and focuses can invest anywhere between $100 thousand USD and a couple million to get early stage focused ultrasound using therapeutics to the proof of concept stage. The foundation invests globally.

The foundation is interested in technologies that utilize focused ultrasound and can aid in the adoption of this technology as a standard in the therapeutics world. This includes the use of focused ultrasound as a drug delivery mechanism, as part of a therapy (non-invasive thermal ablation), etc. Within these sectors, the firm is particularly interested in neurological indications, cancer indications, immunotherapies, and pediatric indications. The firm currently focuses on pre-clinical and phase I assets, but is also willing to invest in phase II assets that are nearing a significant milestone.

The foundation is looking for a team that is capable of taking the technology to a proof of concept stage as their main goal while investing is to accelerate the adoption of ultrasound for use in therapeutics.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A fully integrated pharmaceutical business that launched as a wholly-owned subsidiary of a large South Korea-based corporate is actively engaging in partnering with early-stage companies. The corporate is one of the largest conglomerates in South Korea, and a well-established leader in the food, feed, and biotech industry. Historically, the firm has had a successful track record of commercializing new drugs. The firm is actively seeking in-licensing and collaborative opportunities to add to their growing pipeline that covers areas of high, unmet medical need. The firm will seek opportunities globally.

The firm is currently seeking early-stage, in-licensing opportunities with strongest interest in antibodies and cell/gene therapies in nonalcoholic steatohepatitis (NASH) or immuno-oncology.

The firm is seeking to partner with early-stage companies developing novel therapeutics with management teams of strong scientific background and expertise.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with main offices in Shanghai, China is currently managing two angel funds. On average, the initial size of investment is in the $1-6M range, but the firm has the capacity to invest more in companies they identify as a strong fit. The firm has 5 innovation centers across China focusing on different special areas in Life Sciences and Healthcare. With over 8 years operating experience of international medical technology incubators, the firm looks to tailor its services to help portfolio companies reaching key value-added milestones. The firm will consider opportunities based in China and around the globe, companies within a strong China angle involvement is their sweet spot. The firm is actively seeking distribution rights and new investment opportunities.

The firm is a flexible and opportunistic investor that is currently considering Therapeutics, Medical Devices, Diagnostics, Healthcare IT, and Biotechnology R&D Services. The firm is opportunistic in terms of subsector and indication and is willing to consider companies targeting orphan indications. The firm is open to novel medical devices of all FDA regulatory pathways, including 510k and PMA. In terms of therapeutics, the firm will look at products in pre-clinical stages. Regarding medical devices and diagnostics, the firm will invest at any stage of development.

The firm will invest in privately held companies only, and the firm can participate as either lead or co-investor. The firm has no specific requirements for the management team. Team members who speak Mandarin may be a plus but is not required. The firm may take a board seat in applicable cases.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A life sciences venture capital with offices in Central Hong Kong currently manages a fund with $330 million assets under management and is actively seeking investment opportunities. On average, the size of investment is $10-20M in venture rounds. The firm prefers to act as the lead investor but is also open to co-investing. The firm can invest both public and private companies in a broad variety of types and transaction structures including growth capital, buyouts, late-stage developments (with proof of concept), and recapitalizations. The firm looks for companies located around the globe, with a preference in the USA and China. The firm is actively seeking new investment opportunities.

The firm is a flexible and opportunistic investor that is currently considering Therapeutics, Medical Devices, and Diagnostics companies. The firm is opportunistic in terms of subsector and indication and is willing to consider companies targeting orphan indications. The firm is open to novel medical devices of all FDA regulatory pathways, including 510k and PMA. The firm is strongly interested in AI-driven medical devices. The firm is willing to invest companies at any stage of development.

The firm prefers management team with strong scientific background and expertise, successful track records would be a plus but is not required. The firm generally takes a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in Shenzhen, China was founded in the 1990s and currently has about 1.5 billion RMB in assets under management. The firm is currently investing out of their $30 million USD fund. The firm focuses on Series A-B deals within the USA, Canada, and China and typically invests $2-5 million USD per deal. The firm typically co-invests, but is willing to lead in specific situations.

The firm is opportunistic within the therapeutics and medical technology domains. However, for therapeutics, the firm focuses mostly on assets that are currently in Phase I or Phase II clinical trials. For Medical Devices, they prefer technologies that already have 510k or PMA clearance. Most importantly though, when investing, the firm requires that the technology has strong clinical evidence of efficacy. Strong evidence of efficacy is the most important criteria for the firm when investing in therapeutics and medical technology.

The firm is looking for a management team with a strong history of success as serial entrepreneurs or with strong clinical backgrounds. For investment opportunities without FDA clearance, the firm prefers seeing management teams with prior success in achieving FDA approval or candidates who have strong background from big pharma.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An impact investment fund based in San Francisco, California is investing from a $400 million fund, and makes investments in several sectors including cleantech, IT and healthcare. As the firm invests in a variety of sectors and stages, allocations vary considerably but initial investments are typically between $5-15 million. The firm primarily invests in the USA but also has the ability to invest worldwide. The firm typically leads investment rounds but is also open to co-investing as part of a strong syndicate. The firm plans to invest in a total of 25-30 companies from the current fund.

In healthcare, the firm is interested in healthcare IT, medical device and diagnostic startups that have an approved product or a product that does not require FDA approval. The firm also wants to see evidence that the company’s approach has efficacy in achieving a health benefit or impact. While the firm will consider any indication area, the firm has a preference for investing in chronic diseases, including diabetes and prediabetes, and also behavioral conditions.

The firm does not invest in companies that still face regulatory risks for their products. The firm also places a strong emphasis on reimbursement and/or the product having established a revenue generating model.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.